VK2735

Human clinical Weight Loss & Metabolism 2 sources

VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics. Research shows it significantly reduces body weight and improves metabolic markers in clinical trials, positioning it as a potential next-generation treatment for obesity.

01Dosing reference

Amount

Investigational doses vary (e.g., 2.5 mg to 15 mg for SubQ; up to 40 mg for oral in trials)

Frequency

Once weekly (SubQ) or once daily (Oral)

Cycle

Continuous use under clinical supervision (investigational)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Receptor Activation

VK2735 binds to and activates both GLP-1 and GIP receptors in the body.

Metabolic Regulation

Activation of these receptors slows gastric emptying, increases insulin secretion in response to meals, and signals fullness to the brain.

Weight and Glucose Reduction

These combined effects lead to reduced caloric intake, significant weight loss, and improved glycemic control.

03Human evidence

Significant weight loss in Phase 2 VENTURE trial.

Patients receiving subcutaneous VK2735 achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks.

Promising results with oral formulation.

A Phase 1 trial of oral VK2735 showed up to 3.3% placebo-adjusted weight loss after 28 days, with a favorable safety profile.

04Preclinical evidence

Synergistic effects on weight and glucose.

Animal models of obesity demonstrated that dual GLP-1/GIP agonism by VK2735 produced greater weight loss and glucose lowering than GLP-1 agonism alone.

Preservation of lean mass.

Rodent studies suggested that the addition of GIP agonism may help preserve lean body mass during weight loss compared to selective GLP-1 agonists.

05What is known vs. unknown

Reasonably established

VK2735 targets both GLP-1 and GIP receptors, similar to tirzepatide.
It is being developed in both subcutaneous (injectable) and oral formulations.
Clinical trials have demonstrated rapid and significant weight loss over relatively short periods (e.g., 13 weeks).
The safety profile appears consistent with other incretin-based therapies, primarily involving mild to moderate gastrointestinal side effects.

Unknowns & limits

Long-term safety and efficacy data beyond Phase 2 trials are not yet available.
The exact cardiovascular benefits or risks compared to established GLP-1 agonists remain to be determined in larger outcome trials.
The optimal dosing strategy for the oral formulation is still under investigation.

06Safety & regulatory context

Regulatory statusVK2735 is an investigational drug and is not yet approved by the FDA or other regulatory agencies. In clinical trials, the most common side effects have been gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are typical for the incretin class. These side effects are generally mild to moderate and tend to occur during dose escalation. As with other GLP-1/GIP agonists, there may be theoretical risks of pancreatitis or thyroid C-cell tumors, though long-term data for VK2735 is pending.

07Compared with Tirzepatide

VK2735 vs. Tirzepatide

Key difference

Both are dual GLP-1/GIP agonists, but VK2735 is being developed simultaneously as both a subcutaneous injection and an oral pill, whereas tirzepatide is currently only approved as an injection.

When researchers discuss each

Researchers discuss tirzepatide as the established, FDA-approved dual agonist benchmark, while VK2735 is discussed as a promising next-generation candidate with potential best-in-class efficacy and a convenient oral option.

08Glossary

Incretin

Metabolic hormones that stimulate a decrease in blood glucose levels and are released after eating.

Dual Agonist

A compound that activates two different cellular receptors simultaneously, in this case, GLP-1 and GIP.

GLP-1

Glucagon-like peptide-1, a hormone that promotes insulin secretion, slows stomach emptying, and reduces appetite.

GIP

Glucose-dependent insulinotropic polypeptide, a hormone that complements GLP-1 by enhancing insulin response and potentially improving fat metabolism.

09Knowledge check

Q1What two receptors does VK2735 target?

Q2Which formulation of VK2735 is currently being investigated in clinical trials?

Q3Which of the following limitations about VK2735 is explicitly stated in the dossier?

Q4When researchers discuss tirzepatide compared with VK2735, how is tirzepatide typically characterized in the dossier?

Q5Which safety or regulatory statement about VK2735 is supported by the dossier?

10Sources

ClinicalTrials.gov A Study of VK2735 in Patients With Obesity (VENTURE)
ClinicalTrials.gov A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.